BBIO vs JAZZ
BridgeBio Pharma, Inc. and Jazz Pharmaceuticals plc, both Healthcare
Jazz Pharmaceuticals plc is the larger company at $14B against $13B. Over the past year JAZZ returned +123% against +73% for BBIO. Ryufin's sector-relative Smart Score puts JAZZ ahead, 6/10 against 3/10.
| Figure | BBIO | JAZZ |
|---|---|---|
| Last close | $79.36 | $249 |
| Market cap | $13B | $14B |
| 1-year return | +73% | +123% |
| 5-year return | +52% | +46% |
| Ryufin Smart Scoresector-relative, 1–10 | 3/10 | 6/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Jazz Pharmaceuticals plc
Revenue of $1.1B in Q1 2026, net income $293M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.